XML Sitemap

This is a XML Sitemap which is supposed to be processed by search engines which follow the XML Sitemap standard like Ask.com, Bing, Google and Yahoo.
It was generated using the WordPress content management system and the Google Sitemap Generator Plugin by Arne Brachhold.
You can find more information about XML sitemaps on sitemaps.org and Google's list of sitemap programs.

URLPriorityChange frequencyLast modified (GMT)
https://xconomy.com/raleigh-durham/2019/09/30/dova-pharmaceuticals-agrees-to-sobi-acquisition-shares-jump-38/60%Monthly2019-09-30 21:30
https://xconomy.com/boston/2019/09/27/beam-therapeutics-preps-ipo-and-sheds-light-on-its-gene-editing-drugs/60%Monthly2019-09-28 01:27
https://xconomy.com/san-diego/2019/09/27/at-venture-summit-3-takeaways-for-entrepreneurs-from-true-ventures-phil-black/60%Monthly2019-09-27 16:18
https://xconomy.com/boston/2019/09/27/genfit-promotes-dean-hum-to-president-as-it-preps-us-nash-plans/60%Monthly2019-09-27 15:34
https://xconomy.com/boston/2019/09/27/kaleido-exec-brumm-is-stepping-down-to-become-ceo-of-another-biotech/60%Monthly2019-09-27 15:16
https://xconomy.com/national/2019/09/27/biotech-roundup-vaping-toll-rises-nash-news-akcea-shakeup-more/60%Monthly2019-09-27 10:36
https://xconomy.com/san-diego/2019/09/26/medallia-acquires-hospitality-software-startup-zingle-for-42m/60%Monthly2019-09-27 21:40
https://xconomy.com/san-francisco/2019/09/26/meissa-scores-30m-to-test-vaccine-for-dangerous-respiratory-virus/60%Monthly2019-09-26 21:29
https://xconomy.com/boston/2019/09/26/enanta-steps-forward-in-nash-race-with-unclear-prospects/60%Monthly2019-09-26 12:23
https://xconomy.com/san-diego/2019/09/25/report-ipo-activity-picking-back-up-following-quiet-volatile-q3/60%Monthly2019-09-26 01:07
https://xconomy.com/new-york/2019/09/25/hookipa-pharma-names-christine-baker-cbo-roman-necina-cto/60%Monthly2019-09-25 22:33
https://xconomy.com/boston/2019/09/25/catabasis-names-ex-alkermes-exec-komjathy-chief-commercial-officer/60%Monthly2019-09-26 19:09
https://xconomy.com/texas/2019/09/25/cyberfortress-adds-3m-seed-round-for-cybersecurity-insurance-tech/60%Monthly2019-09-25 17:22
https://xconomy.com/new-york/2019/09/25/medco-preps-for-fda-filing-as-cholesterol-drug-clears-last-two-tests/60%Monthly2019-09-25 13:08
https://xconomy.com/san-francisco/2019/09/25/tigergraph-raises-32m-to-extend-graph-database-use-to-businesses/60%Monthly2019-09-25 12:56
https://xconomy.com/seattle/2019/09/24/amazon-launches-virtual-clinic-to-help-its-employees-get-healthcare/60%Monthly2019-09-25 16:51
https://xconomy.com/boston/2019/09/24/forma-therapeutics-adds-kelly-shegog-and-wadlinger-to-c-suite/60%Monthly2019-09-24 17:05
https://xconomy.com/boston/2019/09/24/concert-pharma-names-ex-merrimack-exec-munsie-chief-legal-officer/60%Monthly2019-09-24 16:59
https://xconomy.com/boston/2019/09/24/drug-pricing-innovation-investment-and-the-public-good/60%Monthly2019-09-27 13:59
https://xconomy.com/san-francisco/2019/09/23/katerra-to-make-ultra-strong-wood-panels-at-new-factory-in-wa/60%Monthly2019-09-24 18:38
https://xconomy.com/wisconsin/2019/09/23/fda-decision-expands-market-for-exact-sciences-cologuard-test/60%Monthly2019-09-23 23:45
https://xconomy.com/san-francisco/2019/09/23/amgens-galimi-jumps-to-adicet-bio-to-become-chief-medical-officer/60%Monthly2019-09-24 17:08
https://xconomy.com/boston/2019/09/23/omega-therapeutics-taps-ex-macrolide-pharma-exec-karande-for-ceo/60%Monthly2019-09-23 22:35
https://xconomy.com/boston/2019/09/23/akcea-shakes-up-management-and-shows-three-executives-the-door/60%Monthly2019-09-23 16:02
https://xconomy.com/seattle/2019/09/23/an-entrepreneurs-quest-to-make-seattle-a-genome-sciences-hub/60%Monthly2019-09-23 14:14
https://xconomy.com/boston/2019/09/23/flagships-omega-debuts-with-plans-to-take-epigenetics-a-step-further/60%Monthly2019-09-23 11:18
https://xconomy.com/boston/2019/09/23/enough-with-the-insanity-we-need-to-fix-cybersecurity-now/60%Monthly2019-09-20 19:33
https://xconomy.com/san-diego/2019/09/20/qa-new-rady-dean-ordonez-on-schools-growth-startups-ethics-more/60%Monthly2019-09-20 15:58
https://xconomy.com/national/2019/09/20/bio-roundup-pelosis-reveal-alders-deal-biogens-fails-more/60%Monthly2019-09-20 10:00
https://xconomy.com/boston/2019/09/20/boston-tech-watch-datarobot-ibm-mit-firefly-aliro-embr-more/60%Monthly2019-09-19 22:00
https://xconomy.com/san-francisco/2019/09/19/five-primes-knickerbocker-resigns-director-ringo-named-interim-ceo/60%Monthly2019-09-19 22:21
https://xconomy.com/seattle/2019/09/19/amazon-sets-electric-vehicle-carbon-footprint-goals-amid-criticism/60%Monthly2019-09-19 22:19
https://xconomy.com/boston/2019/09/19/sr-ones-roberts-tapped-as-chief-scientific-officer-of-black-diamond/60%Monthly2019-09-23 18:20
https://xconomy.com/san-francisco/2019/09/19/from-discovery-to-clinic-tools-techniques-to-maximize-biologic-drug-candidate-success-2/60%Monthly2019-09-19 20:31
https://xconomy.com/san-francisco/2019/09/19/cymabay-chief-medical-officer-boudes-to-depart-at-septembers-end/60%Monthly2019-09-19 20:24
https://xconomy.com/national/2019/09/19/pelosi-dems-unveil-price-plan-are-25-drugs-enough-for-negotiation/60%Monthly2019-09-19 20:21
https://xconomy.com/boston/2019/09/19/gemini-therapeutics-picks-orchards-jason-meyenburg-for-ceo/60%Monthly2019-09-19 20:16
https://xconomy.com/boston/2019/09/19/foghorn-therapeutics-adds-samuel-agresta-allan-reine-to-c-suite/60%Monthly2019-09-19 19:56
https://xconomy.com/san-francisco/2019/09/19/retrophins-neil-mcfarlane-named-adamas-ceo-succeeding-gregory-went/60%Monthly2019-09-19 19:50
https://xconomy.com/boston/2019/09/19/new-deals-may-double-240m-funding-for-mit-ibm-ai-lab-director-says/60%Monthly2019-09-19 20:18
https://xconomy.com/san-diego/2019/09/19/from-discovery-to-clinic-tools-techniques-to-maximize-biologic-drug-candidate-success/60%Monthly2019-09-19 18:59
https://xconomy.com/boston/2019/09/19/high-flying-ginkgo-nets-another-290m-to-program-cells-like-computers/60%Monthly2019-09-19 14:46
https://xconomy.com/san-diego/2019/09/19/eying-extra-dna-as-cancer-driver-boundless-bio-adds-46m-funding/60%Monthly2019-09-19 11:27
https://xconomy.com/wisconsin/2019/09/18/wi-watchlist-msi-data-cellular-dynamics-warf-redox-more/60%Monthly2019-09-19 17:14
https://xconomy.com/boston/2019/09/18/aliro-technologies-lands-2-7m-to-help-developers-go-quantum/60%Monthly2019-09-18 13:59
https://xconomy.com/seattle/2019/09/17/gilliland-to-step-down-as-head-of-fred-hutch-in-2020/60%Monthly2019-09-19 14:47
https://xconomy.com/texas/2019/09/17/hmss-36m-deal-to-buy-vitreoshealth-combines-complementary-firms/60%Monthly2019-09-17 20:56
https://xconomy.com/seattle/2019/09/17/innovations-in-healthcare-xconomy-seattle-life-science-forum-nov-6-2019/60%Monthly2019-09-17 16:46
https://xconomy.com/san-diego/2019/09/17/automated-trucking-company-tusimple-adds-120m-more-from-investors/60%Monthly2019-09-17 15:54
https://xconomy.com/san-diego/2019/09/17/amplyx-inks-novartis-deal-for-another-compromised-immune-system-drug/60%Monthly2019-09-17 04:52
https://xconomy.com/national/2019/09/16/lundbeck-paying-nearly-2b-for-alder-to-follow-migraine-rivals-to-market/60%Monthly2019-09-17 01:09
https://xconomy.com/san-francisco/2019/09/16/why-menlo-ventures-backed-its-first-construction-tech-firm/60%Monthly2019-09-18 20:53
https://xconomy.com/san-francisco/2019/09/13/advisory-body-backs-aimmune-peanut-allergy-drug-next-up-the-fda/60%Monthly2019-09-14 02:46
https://xconomy.com/boston/2019/09/13/baceless-eisai-biogen-pull-plug-on-alzheimers-drug-in-final-stage/60%Monthly2019-09-20 05:06
https://xconomy.com/san-francisco/2019/09/13/cloudflares-525m-ipo-emboldens-already-confident-internet-booster/60%Monthly2019-09-13 21:11
https://xconomy.com/boston/2019/09/13/boston-tech-watch-neural-galaxy-link-ventures-more-epstein-fallout/60%Monthly2019-09-13 11:59
https://xconomy.com/national/2019/09/13/bio-roundup-award-winners-lung-data-dems-on-drug-pricing-more/60%Monthly2019-09-13 10:46
https://xconomy.com/wisconsin/2019/09/13/booming-cs-demand-brings-ex-acquia-ceo-back-to-his-uw-roots/60%Monthly2019-09-13 12:12
https://xconomy.com/san-francisco/2019/09/12/springworks-and-satsuma-boost-this-weeks-biotech-ipo-haul-to-595m/60%Monthly2019-09-13 17:58
https://xconomy.com/boston/2019/09/12/the-winners-of-the-2019-xconomy-awards-boston-are/60%Monthly2019-09-13 00:24
https://xconomy.com/san-diego/2019/09/12/tocagen-stock-tanks-after-gene-therapy-drug-for-brain-cancer-fails/60%Monthly2019-09-12 18:15
https://xconomy.com/boston/2019/09/12/john-halamka-livongo-health-ai-progress-at-x%c2%b7con-on-oct-22/60%Monthly2019-09-11 18:52
https://xconomy.com/seattle/2019/09/11/as-more-grocers-embrace-tech-swiftly-snags-15m-to-launch-in-seattle/60%Monthly2019-09-13 17:10
https://xconomy.com/san-francisco/2019/09/11/fda-doesnt-shell-peanut-allergy-drug-pre-hearing-aimmune-shares-climb/60%Monthly2019-09-12 14:40
https://xconomy.com/san-diego/2019/09/11/after-investing-gsk-to-buy-out-celiac-drug-developer-sitari-pharma/60%Monthly2019-09-11 18:47
https://xconomy.com/boston/2019/09/11/phil-sharp-crispring-the-heart-the-duchenne-data-gap-on-oct-17/60%Monthly2019-09-12 11:19
https://xconomy.com/national/2019/09/10/after-first-look-at-house-drug-plan-stocks-rise-slightly/60%Monthly2019-09-10 21:53
https://xconomy.com/san-francisco/2019/09/10/blackthorn-therapeutics-names-monique-levy-chief-strategy-officer/60%Monthly2019-09-10 16:01
https://xconomy.com/national/2019/09/10/herceptin-inventors-immunology-pioneers-take-home-2019-lasker-awards/60%Monthly2019-09-10 13:21
https://xconomy.com/boston/2019/09/10/shopify-buys-6-river-systems-for-450m-to-boost-new-fulfillment-centers/60%Monthly2019-09-10 13:26
https://xconomy.com/san-francisco/2019/09/10/challenging-crispr-trucode-raises-34m-for-new-gene-editing-system/60%Monthly2019-09-10 16:07
https://xconomy.com/san-diego/2019/09/10/san-diego-life-sciences-roundup-sgi-dna-zeakal-delmar-pharma-more/60%Monthly2019-09-10 06:33
https://xconomy.com/boston/2019/09/10/your-car-is-hackable-here-are-three-steps-you-can-take/60%Monthly2019-09-10 15:52
https://xconomy.com/seattle/2019/09/09/amazon-with-more-wa-workers-than-microsoft-eyes-adding-10k-more/60%Monthly2019-09-10 16:51
https://xconomy.com/san-diego/2019/09/09/acadia-stock-jumps-on-positive-dementia-related-psychosis-drug-data/60%Monthly2019-09-09 22:08
https://xconomy.com/boston/2019/09/09/joi-ito-media-lab-resign-jeffrey-epstein-knight-macarthur-pretech-nytimes-harvard/60%Monthly2019-09-10 17:09
https://xconomy.com/boston/2019/09/09/genfit-names-carol-addy-to-chief-medical-officer-role/60%Monthly2019-09-09 17:06
https://xconomy.com/boston/2019/09/09/as-new-ceo-of-cerevel-coles-moves-from-one-neuro-startup-to-another/60%Monthly2019-09-09 14:25
https://xconomy.com/national/2019/09/09/at-big-lung-cancer-meeting-lights-shine-on-kras-drug-combos-more/60%Monthly2019-09-09 12:44
https://xconomy.com/seattle/2019/09/06/home-buying-tech-startup-savvy-lane-lands-2m-for-west-coast-growth/60%Monthly2019-09-07 00:58
https://xconomy.com/boston/2019/09/06/frequency-plans-ipo-for-hearing-loss-drug-more-regenerative-meds/60%Monthly2019-09-07 15:36
https://xconomy.com/national/2019/09/06/bio-roundup-medcos-pricing-plan-vertexs-gamble-ubiome-undone/60%Monthly2019-09-06 11:17
https://xconomy.com/boston/2019/09/06/boston-tech-watch-mit-epstein-notarize-cash-new-carbonite-execs/60%Monthly2019-09-05 18:30
https://xconomy.com/wisconsin/2019/09/06/wi-watchlist-epic-frontdesk-shine-startingblock-madison-more/60%Monthly2019-09-05 23:21
https://xconomy.com/boston/2019/09/05/novartis-ifm-team-up-again-with-buyout-option-for-autoimmune-rd/60%Monthly2019-09-05 15:33
https://xconomy.com/san-diego/2019/09/05/startup-aquacycl-raises-4m-to-more-efficiently-treat-wastewater/60%Monthly2019-09-05 02:30
https://xconomy.com/boston/2019/09/05/cogito-raises-20m-to-expand-call-center-emotional-intelligence/60%Monthly2019-09-05 01:22
https://xconomy.com/san-francisco/2019/09/04/sfs-ginger-raises-35m-in-burgeoning-digital-therapeutics-market/60%Monthly2019-09-05 13:23
https://xconomy.com/boston/2019/09/04/synlogics-c-suite-adds-richard-riese-cfo-todd-shegog-to-depart/60%Monthly2019-09-04 21:46
https://xconomy.com/seattle/2019/09/04/as-clean-power-buying-surges-levelten-helps-firms-track-energy-data/60%Monthly2019-09-04 20:53
https://xconomy.com/san-francisco/2019/09/04/bankrupt-ubiome-says-founders-may-have-misled-investors/60%Monthly2019-09-05 05:22
https://xconomy.com/san-francisco/2019/09/04/bolt-biotherapeutics-taps-ex-alder-executive-randy-schatzman-as-ceo/60%Monthly2019-09-04 19:23
https://xconomy.com/boston/2019/09/04/former-nightstar-exec-gregory-robinson-joins-akouos-as-chief-scientific-officer/60%Monthly2019-09-04 19:17
https://xconomy.com/san-francisco/2019/09/03/vir-bio-plans-ipo-to-fund-clinical-trials-of-infectious-disease-drugs/60%Monthly2019-09-06 01:52
https://xconomy.com/boston/2019/09/03/accent-therapeutics-taps-tangos-shakti-narayan-for-ceo/60%Monthly2019-09-04 14:38
https://xconomy.com/texas/2019/09/03/former-alnylam-executive-soni-joins-reata-pharmaceuticals-as-cfo/60%Monthly2019-09-04 14:35
https://xconomy.com/san-diego/2019/09/03/aristea-therapeutics-taps-nihar-bhakta-as-chief-medical-officer/60%Monthly2019-09-04 14:40
https://xconomy.com/boston/2019/09/03/vertex-bets-950m-on-semma-and-a-stem-cell-therapy-for-diabetes/60%Monthly2019-09-04 16:34
https://xconomy.com/boston/2019/09/03/with-fdas-eye-on-jak-drugs-concert-pharma-moves-one-ahead-for-hair-loss/60%Monthly2019-09-03 10:59
https://xconomy.com/new-york/2019/09/02/as-cholesterol-drug-aces-big-test-medco-ceo-open-to-flexible-pricing/60%Monthly2019-09-03 11:13